Get started

ARNA

ARNA 40% gains BEST LEVEL TO BUY (STOCKS)before we kick start the update. your upvotes/subs are appreciated. Why get subbed to to me on Tradingview? -15+ years real live trading experience -TOP Author on TradingView -professional chart break downs -key levels -no junk on my charts -frequent updates -covering FX/crypto/US stocks -24/7 uptime so constant updates So without further due. Keep it short/simple and to the point. ARNA 40% gains BEST LEVEL TO BUY (STOCKS) IMPORTANT NOTE: this is speculative setup. results not guaranteed. do your own due dill. at all times please use a stop loss. ARNA daily chart review. expecting overhead resistance to trigger soon and a subsequent pullback to FILL GAP / trigger mirror S/R key level at/near 45 USD. this is best reload point for bulls. 40% upside later. BUY/HOLD until TP. SPECULATIVE SETUP. USE TIGHT SL. good luck traders! get subbed to stay tuned for all the latest updates. also add likes to support my efforts, thank you.
ALong
by ProjectSyndicate
1
AMMJ Target 5.00 (Very high net profit margins+growth) #MJ Quarterly Semi-Annual Annual (Values in 000s | USD) Period Ending Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Total Revenue 990 952 617 339 Cost of Revenue 163 133 146 106 Gross Profit 826 819 470 233 Operating Expenses Research and Development 63 0 0 0 Sales, General and Admin. 435 478 679 413 Non-Recurring Items - - - - Other - - - - Operating Income 317 329 (214) (189) Income From Continuing Operations Add'l Income/Expense Items - - 8 (40) Earnings Before Interest and Tax 317 329 (214) (189) Interest Expense - - 0 - Earnings Before Tax 317 329 (206) (235) Income Tax - 0 0 - Minority Interest - - - - Equity Earnings Unconsolidated Subsidiary - - - - Net Income Cont. Operations 317 329 (206) (235) Non Recurring Events Discontinued Operations - - - - Extraordinary Items - - - - Effect of Accounting Changes - - - - Other Items - - - - Net Income 317 329 (206) (235) Preferred Stock and Other Adjustments - - - - Net Income Applicable to Common Shareholders 317 329 (206) (235) Assets Current Assets Cash and Cash Equivalents 1,877 1,675 1,663 751 Short Term Investments - - - - Net Receivables 404 193 117 164 Inventory 30 25 28 42 Other Current Assets 14 17 19 9 Total Current Assets 2,326 1,912 1,828 967 Long Term Investments - - - - Property Plant and Equipment 12 8 10 11 Goodwill - - - - Intangible Assets - - - - Accumulated Amortization - - - - Other Assets 4 4 59 4 Deferred Long Term Asset Charges - - - - Total Assets 2,344 1,925 1,898 983 Liabilities Current Liabilities Accounts Payable 34 130 228 92 Short Term and Current Long Term Debt - - - 0 Other Current Liabilities 57 12 434 222 Total Current Liabilities 92 142 663 329 Long Term Debt - - - - Other Liabilities - - - - Deferred Long Term Liability Charges - - - - Minority Interest - - - - Negative Goodwill - - - - Total Liabilities 92 142 663 329 Stockholders' Equity Misc. Stock Options Warrants - - - - Redeemable Preferred Stock - - - - Preferred Stock 0 0 - 0 Common Stock 0 0 0 0 Retained Earnings (4,235) (4,611) (4,940) (4,734) Treasury Stock - - - - Capital Surplus 6,486 6,393 6,176 5,389 Other Stockholder Equity - - - - Total Stockholder Equity 2,251 1,783 1,235 654 Net Tangible Assets 2,251 1,783 1,235 654
OTC:AMMJLong
by StockPicksNYC98
Need more pharmaceutical investments?Chaps... Arena is now a pipeline company, with three phase 2's this year for now the algos have this until we get see some results and we let loose. JPM update was the golden egg, please see slides for more information (www.sec.gov) Poor $OREX longs never learn, holders now after reading the ARNA CC transcript its like a Rolls Royce to a Ford KA, ARNA has eisai paying all exp. and still takes 20% of revs,and the PIPELINE is the rainmaker! Overview on pharma as an industry? Alzheimers disease is the global emergency and health in general we are all living longer and making it to be 70 and 80 and eventually 130 and150 years old. The problem is the focus, Parkinsons, Alzheimers and ageing in general take up so much time. Governments are satisfied with dealing with the research and leaving the application side to the pharma companies, that is not a great connection. For example anti ageing is very hard in our current framework to achieve as a company, the FDA is not set up for it, the patent office is not set up for it. You could make a great anti ageing drug and lose all of your money trying to back. You need a 10-20 year project to defeat Alzheimers, it is the one case where government spending is actually warranted, like the moon landing. Its a wonderful thing for society, the world should start a drug company to focus on these areas, the one area they could partner up. In the same breath we have done a great job for cancer research has been almost miraculous, PD1 inhibitors have been really successful and cancer in general is starting to be done with.
ALong
by TheBanker
9